Lexicon Pharmaceuticals | LXRX - Fremdkapital





Fremdkapital Veränderung Datum
Abbott USD 9.9B 1.7B 2025-12
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Akebia Therapeutics USD 48.25M 609K 2025-12
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
AstraZeneca USD 26.14B 19.58B 2025-12
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Illumina USD 1.49B 496M 2025-12
Insmed USD 540.96M 1.24M 2025-12
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
J&J USD 39.44B 30M 2025-12
Lexicon Pharmaceuticals USD 49.41M 7.1M 2025-12
MacroGenics USD 70M 256K 2025-12
MannKind USD 548.44M 244.79M 2025-12
Merck USD 39.97B 6B 2025-09
Moderna USD 610M 584M 2025-12
Novartis USD 29.59B 5.35B 2025-12
PTC Therapeutics USD 2.03B 193.22M 2025-12
Puma Biotechnology USD 10.87M 222K 2025-06
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Thermo Fisher Scientific USD 35.85B 4B 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12